March 25, 2022 -- KSQ Therapeutics will give an oral presentation at the upcoming American Association for Cancer Research (AACR) 2022 annual meeting, held April 8-13.
The company will provide an overview of preclinical data on KSQ-4279, its USP1 inhibitor, as part of the ongoing phase I clinical trial of KSQ-4279 in advanced solid tumors.
USP1 was identified by KSQ's CRISPRomics platform as a novel synthetic lethal target in cancers with certain types of genomic instability, the company said.
The company's presentation will be on April 12 at 1:05-1:20 p.m. CT.